-
1
-
-
1842413105
-
A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project
-
A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood. 1997; 89: 3909-3918.
-
(1997)
Blood
, vol.89
, pp. 3909-3918
-
-
-
2
-
-
54849426881
-
Classification updates and clinical investigations in indolent non-Hodgkin lymphoma
-
Cheson BD,. Classification updates and clinical investigations in indolent non-Hodgkin lymphoma. Clin Adv Hematol Oncol. 2008; 6: 4-6.
-
(2008)
Clin Adv Hematol Oncol
, vol.6
, pp. 4-6
-
-
Cheson, B.D.1
-
3
-
-
0027376013
-
Natural history of and therapy for the indolent non-Hodgkin's lymphomas
-
(5 suppl).
-
Horning SJ,. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol. 1993; 20 (5 suppl 5): 75-88.
-
(1993)
Semin Oncol
, vol.20
, Issue.5
, pp. 75-88
-
-
Horning, S.J.1
-
4
-
-
62449324950
-
Follicular lymphoma in the United States: First report of the national LymphoCare study
-
Friedberg JW, Taylor MD, Cerhan JR, et al. Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol. 2009; 27: 1202-1208.
-
(2009)
J Clin Oncol
, vol.27
, pp. 1202-1208
-
-
Friedberg, J.W.1
Taylor, M.D.2
Cerhan, J.R.3
-
5
-
-
84865835283
-
A comparison of the effectiveness of first-line chemoimmunotherapy regimens for follicular lymphoma (fl) used in the United States [abstract]
-
Abstract 97
-
Nastoupil L, Sinha R, Byrtek M, et al. A comparison of the effectiveness of first-line chemoimmunotherapy regimens for follicular lymphoma (fl) used in the United States [abstract]. Blood. 2011; 118:Page 47. Abstract 97.
-
(2011)
Blood
, vol.118
, pp. 47
-
-
Nastoupil, L.1
Sinha, R.2
Byrtek, M.3
-
6
-
-
0028835315
-
Patterns of survival in patients with recurrent follicular lymphoma: A 20-year study from a single center
-
Johnson PW, Rohatiner AZ, Whelan JS, et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol. 1995; 13: 140-147.
-
(1995)
J Clin Oncol
, vol.13
, pp. 140-147
-
-
Johnson, P.W.1
Rohatiner, A.Z.2
Whelan, J.S.3
-
7
-
-
0037108822
-
Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma
-
3rd, et al.
-
Hainsworth JD, Litchy S, Burris HA, 3rd, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma. J Clin Oncol. 2002; 20: 4261-4267.
-
(2002)
J Clin Oncol
, vol.20
, pp. 4261-4267
-
-
Hainsworth, J.D.1
Litchy, S.2
Burris, H.A.3
-
8
-
-
33749545033
-
Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: Results of a prospective randomized phase 3 intergroup trial
-
van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 2006; 108: 3295-3301.
-
(2006)
Blood
, vol.108
, pp. 3295-3301
-
-
Van Oers, M.H.1
Klasa, R.2
Marcus, R.E.3
-
9
-
-
33845515497
-
German Low Grade Lymphoma Study Group (GLSG). Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas
-
Forstpointner R, Unterhalt M, Dreyling M, et al. German Low Grade Lymphoma Study Group (GLSG). Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood. 2006; 108: 4003-4008.
-
(2006)
Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)
, vol.108
, pp. 4003-4008
-
-
Forstpointner, R.1
Unterhalt, M.2
Dreyling, M.3
-
10
-
-
2942567554
-
Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly ×4 schedule
-
Ghielmini M, Schmitz SF, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly ×4 schedule. Blood. 2004; 103: 4416-4423.
-
(2004)
Blood
, vol.103
, pp. 4416-4423
-
-
Ghielmini, M.1
Schmitz, S.F.2
Cogliatti, S.B.3
-
11
-
-
78650823247
-
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, randomised controlled trial
-
Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011; 377: 42-51.
-
(2011)
Lancet
, vol.377
, pp. 42-51
-
-
Salles, G.1
Seymour, J.F.2
Offner, F.3
-
12
-
-
77956413908
-
Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: Long-term outcome of the EORTC 20981 phase III randomized intergroup study
-
van Oers MH, Van Glabbeke M, Giurgea L, et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol. 2010; 28: 2853-2858.
-
(2010)
J Clin Oncol
, vol.28
, pp. 2853-2858
-
-
Van Oers, M.H.1
Van Glabbeke, M.2
Giurgea, L.3
-
13
-
-
63749097149
-
Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: Results of the randomized phase III ECOG1496 Study
-
Hochster H, Weller E, Gascoyne RD, et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. J Clin Oncol. 2009; 27: 1607-1614.
-
(2009)
J Clin Oncol
, vol.27
, pp. 1607-1614
-
-
Hochster, H.1
Weller, E.2
Gascoyne, R.D.3
-
14
-
-
14544276412
-
Maximizing therapeutic benefit of rituximab: Maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma-A randomized phase II trial of the Minnie Pearl Cancer Research Network
-
Hainsworth JD, Litchy S, Shaffer DW, Lackey VL, Grimaldi M, Greco FA,. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma-a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2005; 23: 1088-1095.
-
(2005)
J Clin Oncol
, vol.23
, pp. 1088-1095
-
-
Hainsworth, J.D.1
Litchy, S.2
Shaffer, D.W.3
Lackey, V.L.4
Grimaldi, M.5
Greco, F.A.6
-
15
-
-
84867400613
-
Results of Eastern Cooperative Oncology Group Protocol E4402 (RESORT): A randomized phase III study comparing 2 different rituximab dosing strategies for low tumor burden follicular lymphoma [abstract]
-
Abstract LBA-6
-
Kahl B, Fangxin H, Williams ME, et al. Results of Eastern Cooperative Oncology Group Protocol E4402 (RESORT): a randomized phase III study comparing 2 different rituximab dosing strategies for low tumor burden follicular lymphoma [abstract]. Blood. 2011; 118:Page. Abstract LBA-6.
-
(2011)
Blood
, vol.118
-
-
Kahl, B.1
Fangxin, H.2
Williams, M.E.3
-
16
-
-
84877359983
-
Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections
-
Casulo C, Maragulia J, Zelenetz AD,. Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. Clin Lymphoma Myeloma Leuk. 2013; 13: 106-111.
-
(2013)
Clin Lymphoma Myeloma Leuk
, vol.13
, pp. 106-111
-
-
Casulo, C.1
Maragulia, J.2
Zelenetz, A.D.3
-
17
-
-
70350776531
-
Good research practices for comparative effectiveness research: Defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: The ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report-Part i
-
Berger ML, Mamdani M, Atkins D, Johnson ML,. Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report-Part I. Value Health. 2009; 12: 1044-1052.
-
(2009)
Value Health
, vol.12
, pp. 1044-1052
-
-
Berger, M.L.1
Mamdani, M.2
Atkins, D.3
Johnson, M.L.4
-
18
-
-
70350780206
-
Good research practices for comparative effectiveness research: Approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment effects using secondary data sources: The International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report-Part II
-
Cox E, Martin BC, Van Staa T, Garbe E, Siebert U, Johnson ML,. Good research practices for comparative effectiveness research: approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment effects using secondary data sources: the International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report-Part II. Value Health. 2009; 12: 1053-1061.
-
(2009)
Value Health
, vol.12
, pp. 1053-1061
-
-
Cox, E.1
Martin, B.C.2
Van Staa, T.3
Garbe, E.4
Siebert, U.5
Johnson, M.L.6
-
19
-
-
70350776529
-
Good research practices for comparative effectiveness research: Analytic methods to improve causal inference from nonrandomized studies of treatment effects using secondary data sources: The ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report-Part III
-
Johnson ML, Crown W, Martin BC, Dormuth CR, Siebert U,. Good research practices for comparative effectiveness research: analytic methods to improve causal inference from nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report-Part III. Value Health. 2009; 12: 1062-1073.
-
(2009)
Value Health
, vol.12
, pp. 1062-1073
-
-
Johnson, M.L.1
Crown, W.2
Martin, B.C.3
Dormuth, C.R.4
Siebert, U.5
|